Literature DB >> 28719256

Therapeutic Dilemma of Refractory Erythema Nodosum Leprosum.

Jianyu Zhu1, Degang Yang2, Chao Shi1, Zhichun Jing1.   

Abstract

AbstractErythema nodosum leprosum (ENL), also known as type II leprosy reaction, is a severe immune-mediated complication of multibacillary leprosy. For ENL, corticosteroids and thalidomide are the mainstays of treatment. Other immunosuppressants, such as clofazimine, cyclosporine, and azathioprine have also been used. Although most patients with ENL respond well to conventional treatments, a small number are refractory to these therapies and have severe morbidity or mortality. We report the case of a 24-year-old man with refractory ENL treated with high-dose corticosteroids for 15 months. The patient developed steroid-dependence and serious adverse effects, and died of an intracranial infection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28719256      PMCID: PMC5462572          DOI: 10.4269/ajtmh.16-0118

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  17 in total

1.  Nocardia farcinica pleuritis in a lepromatous patient with severe necrotizing reaction: an unusual presentation.

Authors:  S Arunthathi; G Ebenezer; E Daniel; S T Sugumaran
Journal:  Int J Lepr Other Mycobact Dis       Date:  2001-06

2.  Global leprosy update, 2013; reducing disease burden.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2014-09-05

3.  Risk factors for erythema nodosum leprosum.

Authors:  R Manandhar; J W LeMaster; P W Roche
Journal:  Int J Lepr Other Mycobact Dis       Date:  1999-09

4.  A fatal case of erythema necroticans.

Authors:  S V Davis; S D Shenoi; C Balachandran; S B Pai
Journal:  Indian J Lepr       Date:  2002 Apr-Jun

Review 5.  Prevention and treatment of systemic glucocorticoid side effects.

Authors:  Siamak Moghadam-Kia; Victoria P Werth
Journal:  Int J Dermatol       Date:  2010-03       Impact factor: 2.736

Review 6.  Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.

Authors:  N Mesaros; P Nordmann; P Plésiat; M Roussel-Delvallez; J Van Eldere; Y Glupczynski; Y Van Laethem; F Jacobs; P Lebecque; A Malfroot; P M Tulkens; F Van Bambeke
Journal:  Clin Microbiol Infect       Date:  2007-01-31       Impact factor: 8.067

Review 7.  The role of thalidomide in the management of erythema nodosum leprosum.

Authors:  Steven L Walker; Michael F R Waters; Diana N J Lockwood
Journal:  Lepr Rev       Date:  2007-09       Impact factor: 0.537

Review 8.  Interventions for erythema nodosum leprosum.

Authors:  Natasja H J Van Veen; Diana N J Lockwood; Wim H van Brakel; Jose Ramirez; Jan Hendrik Richardus
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

9.  ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum.

Authors:  Stephen L Walker; Marivic Balagon; Joydeepa Darlong; Shimelis N Doni; Deanna A Hagge; Vikas Halwai; Annamma John; Saba M Lambert; Armi Maghanoy; Jose A C Nery; Kapil D Neupane; Peter G Nicholls; Vivek V Pai; Pawan Parajuli; Anna M Sales; Euzenir Sarno; Mahesh Shah; Digafe Tsegaye; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2015-09-09

10.  The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study.

Authors:  Stephen L Walker; Eglantine Lebas; Shimelis N Doni; Diana N J Lockwood; Saba M Lambert
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.